The CTLA-4 Pathway in Human Disease: Molecular Mechanisms and Therapeutic Targeting. [PDF]
Negrini S +6 more
europepmc +1 more source
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. [PDF]
Lam G +11 more
europepmc +1 more source
Clinical and genetic features of CTLA-4 haploinsufficiency: a prospective study in China. [PDF]
Liu G +5 more
europepmc +1 more source
Abatacept treatment shows a modulating effect on Treg subsets in LRBA-deficient patients. [PDF]
Donhauser S +6 more
europepmc +1 more source
Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. [PDF]
Hilliquin S +3 more
europepmc +1 more source
Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes. [PDF]
Galderisi A +17 more
europepmc +1 more source
Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major. [PDF]
Khandelwal P +5 more
europepmc +1 more source
The Renal Activity Index for Lupus: Validation for Prediction of Kidney Inflammation in Adult Patients With Lupus Nephritis. [PDF]
O'Connor SK +9 more
europepmc +1 more source
Abatacept today, TMA away: protecting the endothelium. [PDF]
Ngwube A, Abraham A.
europepmc +1 more source
Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate. [PDF]
Yoon J +5 more
europepmc +1 more source

